Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples